首页> 外文期刊>Anti-cancer drugs >A retrospective study of paclitaxel combining nedaplatin chemotherapy for esophageal cancer
【24h】

A retrospective study of paclitaxel combining nedaplatin chemotherapy for esophageal cancer

机译:紫杉醇联合奈达铂化疗治疗食管癌的回顾性研究

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this study was to evaluate the efficacy and tolerability of the combination of paclitaxel and nedaplatin in patients with advanced esophageal cancer. Patients (n=310) with recurrent or metastatic esophageal squamous cell carcinoma, who had a maximum of one previous chemotherapy regimen, were enrolled in this study. All patients had bidimensionally measurable disease. Patients received 175 mg/m(2) of paclitaxel over a 3 h infusion, followed by nedaplatin 80 mg/m(2) in a 1 h infusion on day 1 every 3 weeks for up to 6 treatment cycles. The overall response rate was 47.7%, with complete and partial response rates of 6.1 and 41.7%, respectively. The median time to progression for all patients was 6.8 months (95% confidence interval, 6.2-7.4 months) and the 3-year disease-free survival probability was 3 (15.8%). The major toxicity observed was cumulative neutropenia, with 29% patients developing grade 4 toxicity. There was no treatment-related death. The most common nonhematologic toxicity encountered with this regimen was pain and cumulative peripheral neuropathy, with 26% patients experiencing grade 2 or 3 toxicity. The combination of paclitaxel and nedaplatin shows significant antitumor activity and a favorable toxicity profile in patients with metastatic carcinoma of esophageal cancer. Anti-Cancer Drugs 26: 101-105 (C) 2014 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
机译:这项研究的目的是评估紫杉醇和奈达铂联合治疗晚期食管癌的疗效和耐受性。这项研究纳入了最多有一种以前的化疗方案的复发或转移性食管鳞状细胞癌患者(n = 310)。所有患者均具有二维可测量的疾病。患者在3个小时的输注过程中接受了175 mg / m(2)紫杉醇的治疗,随后每3周在第1天的1 h输注奈达铂80 mg / m(2),最多进行6个治疗周期。总体缓解率为47.7%,完全缓解和部分缓解率分别为6.1和41.7%。所有患者的中位进展时间为6.8个月(95%置信区间为6.2-7.4个月),三年无病生存率为3(15.8%)。观察到的主要毒性是累积性中性粒细胞减少,其中29%的患者发展为4级毒性。没有与治疗有关的死亡。该方案最常见的非血液学毒性是疼痛和累积性周围神经病变,其中26%的患者发生2级或3级毒性。紫杉醇和奈达铂的组合在食管癌转移癌患者中显示出显着的抗肿瘤活性和良好的毒性。 Anti-Cancer Drugs 26:101-105(C)2014 Wolters Kluwer Health垂直栏Lippincott Williams&Wilkins。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号